How Diagnostic Precision in Allergy Care Supports Mental Well-Being
Screening for mental health symptoms in patients with significant allergic disease is not overreach
Bridging the Diagnostic Gap in Allergy Care
By getting to the root cause of patients’ allergies with detailed symptom histories from patients coupled with history, informed comprehensive allergy testing can help uncover hidden allergies, ensure both effective care and smarter resource utilization, and improve patient safety.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
From Pollen to Plate: Identifying Pollen Food Allergy Syndrome
Diagnosing PFAS can be challenging, but establishing a thorough symptom history along with specific IgE blood testing can build a fuller picture of patients’ allergic triggers and sensitizations, helping clinicians develop accurate, tailored treatment recommendations and ultimately improve their patients’ quality of life.
The Overlooked Global Warming Cost We Can’t Ignore
Climate change not only impacts patients with respiratory allergies, but it also has potential broad and emerging impacts on patients with food allergies and overall public health.
Attacking Food Allergies: How Technology can Ease the Path to New Treatments Without the Pain
Advances in flow cytometry could enable researchers to uncover valuable insights about food allergies without allergen exposure.
How Food Allergy Care Has Changed in the Last Decade
The promise of these and other food allergy treatments is immense and research and development, in conjunction with clinical care facilities for food allergy patients, will continue to make more treatment options available for more people in the future.
presented by
The Healthcare Payments Industry Faces a Perception Challenge
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine
ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.
Allermi Raises $3.5M in Seed Funding To Grow DTC Allergy Relief Platform
Allermi's $3.5 million seed funding was led by Nelstone Ventures and included participation from FourSight Capital Partners. The company will use the money to expand nationally.
Online allergy startup raises $1.25M in pre-seed round
Based in San Francisco, Allermi aims to create a national market for a customizable approach to allergy relief pioneered by a California doctor.
Imagine a world without disease
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
EverlyWell garners $2M to add more tests, staff for diagnostic testing startup
Julia Cheek, EverlyWell CEO and cofounder, said in an email that the funding will help the company expand its suite of tests, hire key leadership positions, launch new partnerships and enhance product features this year.
Allergy diagnostics market to reach $3.8bn by 2024
Rising rates of allergies worldwide will cause the global market for allergy diagnostics to nearly triple from $1.3 billion in 2015 to $3.8 billion in 2024, says a new report.
7 biotech and medtech companies confronting the rise of food allergies
From immunotherapies to mobile health apps, here's how biotech and medtech companies are responding to the rising number of children with food allergies.
Innovation is in progress to replace the bulky EpiPen with something more practical
There must be some better, more efficient solutions for the essential use of the EpiPen, and Windgap Medical is working on it.
Morning Read: Abbott readies $25B bid for St Jude Medical, research suggests potential for allergy-free public parks
Drug developer Abbott Laboratories is poised to make a $25 billion bid for medical device maker St Jude Medical, allergy free parks could be a thing in the future.